BioCryst Pharmaceuticals, Inc. provided earnings guidance for the full year 2022. For the period, the company expected full year 2022 net ORLADEYO revenue to be between $255 million and $265 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.405 USD | -3.83% | -1.00% | +6.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.93% | 1.37B | |
+10.71% | 115B | |
+12.68% | 106B | |
-4.39% | 24.69B | |
-1.86% | 21.97B | |
-5.48% | 19.27B | |
-11.70% | 17.56B | |
-39.36% | 17.32B | |
+5.95% | 14.03B | |
+32.92% | 12.13B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022